<a href="https://laohu8.com/S/CDIO">Cardio Diagnostics</a> Holdings Inc. Announces New Clinical Study Using PrecisionCHD™ to Test LODOCO® for Inflammation-Driven Coronary Heart Disease
Cardio Diagnostics Holdings Inc. has announced a new clinical study in collaboration with AGEPHA Pharma to investigate a precision-guided approach to managing inflammation-driven coronary heart disease $(CHD)$. AGEPHA Pharma will provide LODOCO® (low-dose colchicine), an FDA-approved anti-inflammatory medication, for the study. The research will utilize Cardio Diagnostics' PrecisionCHD™ blood test to identify patients with inflammation-driven CHD and evaluate their response to LODOCO® over time. The study aims to use DNA methylation signatures to monitor changes in inflammation. Cardio Diagnostics is currently in the process of selecting clinical sites for the study, which will be registered as a clinical trial. Results of the study have not yet been presented and will be shared in the future upon completion of the trial.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cardio Diagnostics Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250708766264) on July 08, 2025, and is solely responsible for the information contained therein.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。